Cardinal under formal SEC investigation
Executive Summary
Securities & Exchange Commission initiates formal investigation into Cardinal's historical financial information relating in part to the accounting treatment of $22 mil. in revenues received from a vitamin price-fixing litigation settlement. SEC has been investigating the issue informally since October (1"The Pink Sheet" Oct. 13, 2003, In Brief). In April, Cardinal's audit committee retained independent counsel to conduct an internal review...
You may also be interested in...
Cardinal’s SEC request
Wholesaler receives an SEC request for "historical financial and related information," including information on the accounting treatment of a $22 mil. settlement in vitamin price-fixing litigation. Cardinal describes the request as part of an "informal inquiry" and says it is "highly confident in its accounting and financial disclosure practices, and intends to cooperate fully." Questions about the timing of Cardinal's recognition of the settlement funds were raised in April by the Wall Street Journal (1"The Pink Sheet" April 14, 2003, p. 28)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.